SyMRI 12’s regulatory approval by the Taiwan FDA marks SyntheticMR’s strategic expansion into the Asia-Pacific medical imaging market. Credit: SyntheticMR.

SyntheticMR’s quantitative imaging software solution, SyMRI 12, has been granted regulatory approval by the Taiwan Food and Drug Administration (TFDA).

This authorisation facilitates the introduction of SyMRI 12 to the Taiwanese market, marking a significant stride in SyntheticMR’s strategy for regional expansion.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

SyntheticMR CEO Ulrik Harrysson expressed enthusiasm about the new development, stating: “This approval of SyMRI 12 opens new opportunities for us to expand our market presence in Taiwan and the Southeast Asia region. We are excited to offer SyMRI 12 to radiologists in this market, providing them with new insights and enhancing their practice through our unique technology and objective, quantitative data.”

SyntheticMR stated that the TFDA’s approval marks a significant step in enhancing healthcare in Taiwan through advanced imaging technology.

The company’s entry into the Taiwanese market is anticipated to foster improvements in patient care outcomes and bolster its presence in the Asia-Pacific region.

SyMRI 12 is engineered to provide a comprehensive suite of contrast-weighted images and quantitative data from a single rapid scan, which can significantly optimise imaging workflows and support objective decision-making in clinical practices.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

SyntheticMR’s innovative software solutions are claimed to refine clinical decisions, streamline operations, and elevate patient care.

SyntheticMR offers magnetic resonance imaging (MRI) software solutions. Its flagship product, SyMRI, generates adjustable contrast images and quantitative data from a mere five-minute scan. The solution is available in various configurations to cater to different medical needs.

SyMRI NEURO, one of the packages offered, delivers detailed brain imaging, tissue segmentation, and quantitative analysis. In June, SyntheticMR announced the CE marking of SyMRI NEURO version 15, its advanced imaging solution.

SyMRI MSK, another variant, provides imaging and data for knee and spine anatomies. Both SyMRI NEURO and SyMRI MSK have received CE marking, with SyMRI NEURO also cleared by the FDA under the 510(k) provision. Meanwhile, SyMRI 3D is pending 510(k) clearance and has been CE-marked. SyMRI is a registered trademark in both Europe and the US.